2024
Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium
Meagher N, White K, Wilkens L, Bandera E, Berchuck A, Carney M, Cramer D, Cushing-Haugen K, Jordan S, Kaufmann S, Le N, Pike M, Riggan M, Qin B, Rothstein J, Titus L, Winham S, Anton-Culver H, Doherty J, Goode E, Pearce C, Risch H, Webb P, Cook L, Goodman M, Harris H, Le Marchand L, McGuire V, Pharoah P, Sarink D, Schildkraut J, Sieh W, Terry K, Thompson P, Whittemore A, Wu A, Peres L, Merritt M. Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium. American Journal Of Epidemiology 2024, 193: 1242-1252. PMID: 38775277, PMCID: PMC11369223, DOI: 10.1093/aje/kwae076.Peer-Reviewed Original ResearchConceptsOvarian Cancer Association ConsortiumEpithelial ovarian cancer riskNative Hawaiian/Pacific IslanderEpithelial ovarian cancerInverse associationHawaiian/Pacific IslanderRisk associationOdds ratioOvarian cancer riskRisk factor associationsTubal ligationLogistic regression modelsOral contraceptive (OCIslander womenCancer riskFactor associationsWhite participantsPrevention strategiesAsian womenOC useEthnic differencesRisk factorsGynecologic cancerRegression modelsOvarian cancerLetter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’
Kendall P, Lazorwitz A. Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’. Epidemiology And Psychiatric Sciences 2024, 33: e4. PMID: 38299323, PMCID: PMC10894698, DOI: 10.1017/s2045796024000039.Peer-Reviewed Original Research
2023
Comment on “Effects of biological sex and oral contraceptive pill use on cutaneous microvascular endothelial function and nitric oxide-dependent vasodilation in humans”
Colburn A, Stachenfeld N. Comment on “Effects of biological sex and oral contraceptive pill use on cutaneous microvascular endothelial function and nitric oxide-dependent vasodilation in humans”. Journal Of Applied Physiology 2023, 135: 485-486. PMID: 37541850, DOI: 10.1152/japplphysiol.00335.2023.Peer-Reviewed Original ResearchMeSH KeywordsContraceptives, OralFemaleHumansNitric OxideSkinSkin Physiological PhenomenaVasodilationInfluence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study
Taylor H, Alhasan S, Saleem M, Poole S, Jiang F, Longbrake E, Bove R. Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study. Multiple Sclerosis And Related Disorders 2023, 77: 104864. PMID: 37480738, PMCID: PMC11090415, DOI: 10.1016/j.msard.2023.104864.Peer-Reviewed Original ResearchConceptsContinuous oral contraceptivesOral contraceptivesOC usersMenstrual cycleSymptom fluctuationsPilot studyTwo-centre pilot studyRegular menstrual cyclesHormonal contraceptive useIntrauterine device usersMenstrual cycle phaseFuture confirmatory studiesMedian EDSSMean ageGeneralized symptomsHormonal measurementsPerimenstrual periodSymptom SurveyContraceptive useLarge cohortLuteal periodClinical practiceContraceptive choicesParticipant retentionSymptom severityLetter to the Editor in response to: Microvascular endothelial function following the cessation of long‐term oral contraceptive pill use: A case report
Kirby N, Stachenfeld N, Alexander L. Letter to the Editor in response to: Microvascular endothelial function following the cessation of long‐term oral contraceptive pill use: A case report. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2023, 108: 1092-1094. PMID: 37098953, PMCID: PMC10836611, DOI: 10.1113/ep091174.Commentaries, Editorials and LettersExploring technology-based interventions to improve oral contraceptive pill adherence: a cross-sectional survey
Flynn A, Galvao R, Joslin I, McAllister A, Koelper N, Sonalkar S. Exploring technology-based interventions to improve oral contraceptive pill adherence: a cross-sectional survey. The European Journal Of Contraception & Reproductive Health Care 2023, 28: 173-176. PMID: 37013727, DOI: 10.1080/13625187.2023.2191763.Peer-Reviewed Original ResearchLifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Ovarian EpithelialCase-Control StudiesContraceptives, OralFemaleHumansOvarian NeoplasmsParityPregnancyRisk FactorsConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficients
2021
Noninvasive detection of human dehydroepiandrosterone, progesterone and testosterone using LC-MS/MS revealed effects of birth control pills/devices and body weight on ovulatory prediction
Han L, Wemm SE, Shen L, Spink DC, Wulfert E, Cao ZT. Noninvasive detection of human dehydroepiandrosterone, progesterone and testosterone using LC-MS/MS revealed effects of birth control pills/devices and body weight on ovulatory prediction. Journal Of Chromatography B 2021, 1174: 122716. PMID: 33946036, DOI: 10.1016/j.jchromb.2021.122716.Peer-Reviewed Original Research
2020
Contraception and ectopic pregnancy risk: a prospective observational analysis
Schultheis P, Montoya M, Zhao Q, Archer J, Madden T, Peipert J. Contraception and ectopic pregnancy risk: a prospective observational analysis. American Journal Of Obstetrics And Gynecology 2020, 224: 228-229. PMID: 33049248, DOI: 10.1016/j.ajog.2020.10.013.Peer-Reviewed Original ResearchCohort StudiesContraceptive Agents, FemaleContraceptive Devices, FemaleContraceptives, OralDelayed-Action PreparationsDrug ImplantsFemaleHumansIntrauterine Devices, CopperIntrauterine Devices, MedicatedLevonorgestrelMedroxyprogesterone AcetatePregnancyPregnancy, EctopicProportional Hazards ModelsProspective StudiesTransdermal Patch
2019
Familiarity and acceptability of long-acting reversible contraception and contraceptive choice
Paul R, Huysman B, Maddipati R, Madden T. Familiarity and acceptability of long-acting reversible contraception and contraceptive choice. American Journal Of Obstetrics And Gynecology 2019, 222: s884.e1-s884.e9. PMID: 31838124, PMCID: PMC7781163, DOI: 10.1016/j.ajog.2019.11.1266.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsBlack or African AmericanChoice BehaviorContraceptive Agents, HormonalContraceptives, OralDelayed-Action PreparationsDrug ImplantsFemaleHealth Knowledge, Attitudes, PracticeHispanic or LatinoHumansIntrauterine DevicesLong-Acting Reversible ContraceptionMarital StatusMedroxyprogesterone AcetateMiddle AgedPatient Acceptance of Health CareRecognition, PsychologyWhite PeopleYoung AdultConceptsOral contraceptive pillsContraceptive pillsIntrauterine deviceDepo-medroxyprogesteroneContraceptive choicesReversible contraceptionDepo-medroxyprogesterone acetateHealth center populationHealthcare provider visitsHormonal intrauterine deviceHigh acceptabilityMultivariable Poisson regressionQualified health centersPreference-sensitive decisionsReversible contraception methodsCopper intrauterine deviceInterviewer-administered surveySpecific contraceptive methodsChi-square testProvider visitsContraceptive counselingContraceptive careHealth centersContraception methodsContraceptive methodsTen-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence
2017
Oral Contraceptives and Cigarette Smoking: A Review of the Literature and Future Directions
Allen AM, Weinberger AH, Wetherill RR, Howe CL, McKee SA. Oral Contraceptives and Cigarette Smoking: A Review of the Literature and Future Directions. Nicotine & Tobacco Research 2017, 21: 592-601. PMID: 29165663, PMCID: PMC6468133, DOI: 10.1093/ntr/ntx258.Peer-Reviewed Original ResearchMeSH KeywordsAffectBrainCigarette SmokingContraceptives, OralCross-Sectional StudiesFemaleForecastingHumansSmoking CessationConceptsSmoking-related outcomesOC useOral contraceptivesSmoking cessation outcomesCessation outcomesOC usersNovel smoking cessation interventionUse of OCsNicotine metabolismWeight gainSmoking-related symptomsEndogenous sex hormonesSmoking cessation interventionFaster nicotine metabolismCross-sectional studyPhysiological stress responsePremenopausal smokersCurrent smokingPremenopausal womenCessation interventionsCigarette smokingEstradiol levelsSex hormonesGreater oddsFollowing keywordsNeurology Concepts: Young Women and Ischemic Stroke—Evaluation and Management in the Emergency Department
Chang BP, Wira C, Miller J, Akhter M, Barth BE, Willey J, Nentwich L, Madsen T. Neurology Concepts: Young Women and Ischemic Stroke—Evaluation and Management in the Emergency Department. Academic Emergency Medicine 2017, 25: 54-64. PMID: 28646558, PMCID: PMC6415947, DOI: 10.1111/acem.13243.Peer-Reviewed Original ResearchConceptsIschemic strokeYoung womenEmergency departmentRisk factorsSex-specific risk factorsIschemic stroke evaluationAcute ischemic strokeOral contraceptive useBoard-certified emergency physiciansPremenopausal womenAcute settingBroad differentialCerebral hemorrhageStroke evaluationVascular neurologistsNonpregnant individualsPostpartum periodLeading causeEmergency physiciansTimely diagnosisContraceptive useThrombolytic agentsCurrent evidenceStrokeOlder population
2015
Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women?
Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women? Contraception 2015, 91: 380-385. PMID: 25684618, DOI: 10.1016/j.contraception.2015.02.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultContraceptionContraception BehaviorContraceptives, OralFemaleHumansPerceptionSurveys and QuestionnairesYoung AdultConceptsNoncontraceptive benefitsMonths of useContraceptive continuationYoung womenNew contraceptive developmentYoung women ages 13Post-visit surveysWomen ages 13Young adult womenContinuation ratesStudy participantsAdult womenGreater continuationWomenMonthsContraceptive developmentAge 13High rateContraceptionAdolescentsConcordanceBenefits leadPatientsClinicInitiation
2014
Receipt of Prescription Contraception by Commercially Insured Women With Chronic Medical Conditions
DeNoble AE, Hall KS, Xu X, Zochowski MK, Piehl K, Dalton VK. Receipt of Prescription Contraception by Commercially Insured Women With Chronic Medical Conditions. Obstetrics And Gynecology 2014, 123: 1213-1220. PMID: 24807345, PMCID: PMC4169713, DOI: 10.1097/aog.0000000000000279.Peer-Reviewed Original ResearchConceptsChronic medical conditionsPrescription contraceptionChronic conditionsMedical conditionsCommunity-level socioeconomic statusAdministrative claims recordsTotal outpatient visitsInflammatory bowel diseaseSystemic lupus erythematosusCervical cancer screeningMultivariable logistic regressionChronic condition statusBowel diseaseLupus erythematosusOrder of prevalencePharmacy claimsPrimary outcomeOutpatient visitsRheumatoid arthritisAdverse outcomesCancer screeningUnplanned pregnancyObservational studyStudy populationInsured women
2013
Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review
Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 1931-1943. PMID: 24014598, DOI: 10.1158/1055-9965.epi-13-0298.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsContraceptives, OralEndometrial NeoplasmsFemaleHumansOvarian NeoplasmsUterine Cervical NeoplasmsConceptsOral contraceptive useEndometrial cancer incidenceOral contraceptivesContraceptive useCancer incidenceSystematic reviewEndometrial cancerBreast cancerElevated breast cancer riskEndometrial Cancer StudyOral contraceptive exposureHuman papillomavirus infectionBreast cancer incidenceOvarian cancer preventionBreast cancer riskConfidence intervalsStudy inclusion criteriaRisk of breastAHRQ Evidence ReportContraceptive exposurePapillomavirus infectionCervical cancerCochrane DatabaseNonrandomized studyPrimary preventionTwenty-Four–Month Continuation of Reversible Contraception
O'Neil-Callahan M, Peipert J, Zhao Q, Madden T, Secura G. Twenty-Four–Month Continuation of Reversible Contraception. Obstetrics And Gynecology 2013, 122: 1083-1091. PMID: 24104781, PMCID: PMC4012225, DOI: 10.1097/aog.0b013e3182a91f45.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBody Mass IndexCohort StudiesContraceptionContraceptive Agents, FemaleContraceptives, OralFemaleFollow-Up StudiesHumansInterviews as TopicIntrauterine DevicesIntrauterine Devices, CopperLevonorgestrelMedroxyprogesterone AcetateParityProspective StudiesRisk FactorsSocioeconomic FactorsYoung AdultConceptsNon-LARC methodsContinuation ratesContraceptive CHOICE ProjectReversible contraceptionContraceptive methodsFirst-line contraceptive optionProspective observational cohort studyContraceptive method discontinuationImplant continuation ratesMonth continuation ratesObservational cohort studyMonths of enrollmentHigh continuation ratesReversible contraceptive methodsCHOICE ProjectShort-acting methodsCohort studyMethod discontinuationContraceptive optionsLARC methodsUnintended pregnancyIntrauterine deviceCost contraceptionLower riskCopper IUDOral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2013, 31: 4188-4198. PMID: 24145348, DOI: 10.1200/jco.2013.48.9021.Peer-Reviewed Original ResearchMeSH KeywordsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsContraceptives, OralFemaleHeterozygoteHumansMutationOvarian NeoplasmsRisk AssessmentConceptsBRCA1/2 mutation carriersBRCA2 mutation carriersOvarian cancerBreast cancerMutation carriersFamily historyOC useCancer riskSystematic reviewOral contraceptive useHigh-risk womenUse of OCsBreast cancer riskOvarian cancer riskStrong family historyTiming of useOral contraceptivesCochrane DatabaseInverse associationBRCA1/2 mutationsContraceptive useElevated riskGeneral populationUnique citationsMeta-AnalysisVenting the Spleen
Varughese N, Duong A, Emre S, Xu M, Lee AI. Venting the Spleen. New England Journal Of Medicine 2013, 369: 1357-1363. PMID: 24088096, DOI: 10.1056/nejmcps1210943.Peer-Reviewed Original ResearchOral Contraceptive Pills as Primary Prevention for Ovarian Cancer
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. Obstetrics And Gynecology 2013, 122: 139-147. PMID: 23743450, DOI: 10.1097/aog.0b013e318291c235.Peer-Reviewed Original ResearchMeSH KeywordsContraceptives, OralFemaleHumansOvarian NeoplasmsPregnancyPrimary PreventionRiskRisk ManagementConceptsOral contraceptive pillsUse of OCPOvarian cancer incidenceOCP useContraceptive pillsCancer incidenceOvarian cancerDuration-dependent reductionDuration-response relationshipOvarian cancer riskDuration of useCohort studyCochrane DatabasePrimary preventionSTUDY SELECTIONInclusion criteriaCancer riskDiscordant decisionsGeneral populationPrimary analysisSystematic reviewTeam reviewIncidenceSignificant reductionMore years
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply